A Phase 3b Study Evaluating the 24-Hour Intraocular Pressure Lowering Effect of Bimatoprost SR in Patients With Open-Angle Glaucoma or Ocular Hypertension

Trial ID or NCT#



not recruiting iconNOT RECRUITING


This study will evaluate the 24-hour intraocular pressure lowering effect and safety after a single administration of Bimatoprost SR in patients with Open-Angle Glaucoma or Ocular Hypertension

Official Title

An Evaluation of the 24-Hour Intraocular Pressure(IOP)-Lowering Effect of Bimatoprost Sustained-Release(SR) in Participants With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of either OAG or OHT study eye, requiring IOP-lowering treatment - Participant is currently a nonsmoker and has not smoked any nicotine-containing products within the previous 6 months
Exclusion Criteria:
  1. - Current or anticipated enrollment in another investigational drug or device study - Females who are pregnant, nursing, or planning a pregnancy during the study


Ann Caroline Fisher, MD
Ann Caroline Fisher, MD
Glaucoma specialist, Cataract specialist
Clinical Associate Professor, Ophthalmology